Codexis, Inc. (CDXS) News
Filter CDXS News Items
CDXS News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest CDXS News From Around the Web
Below are the latest news stories about Codexis Inc that investors may wish to consider to help them evaluate CDXS as an investment opportunity.
REDWOOD CITY, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2020 financial results after market close on Thursday, August 6, 2020. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update. We encourage participants to pre-register for the conference call using the following link: http://dpregister.com/10146500. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.Those without intern...
Partnership targets accelerating the commercialization of enzymatic DNA synthesis: Codexis invests cash and protein engineering for equity stake in Molecular Assemblies
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
REDWOOD CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of…
Q1 2020 Codexis Inc Earnings Call
Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metabolizing enzymes, announce a Co-Marketing & Enzyme Supply Collaboration Agreement for the production and co-marketing of enzymes for life science applications. The first enzyme is a high-fidelity DNA polymerase, following up on Codexis’ previously announced high performance DNA ligase, which was exclusively licensed to Roche in late 2019. The Codexis-developed DNA polymerase has been engineered to deliver high fidelity and uniformity of coverage, providing an accurate and representative DNA diagnostic result.
REDWOOD CITY, Calif., May 27, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment.
The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.
REDWOOD CITY, Calif., May 11, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare.
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of $12.23.